PURPLE BIOTECH LTD. (PPBT) Form 6-K — Jun 11, 2026
Purple Biotech presented new preclinical data for its lead candidate IM1240 at the EACR 2026 conference, highlighting superior pharmacokinetics and safety compared to non-capped variants. The data supports the company's plan to advance IM1240 to a first-in-human clinical study in 2027. In non-human primate studies, IM1240 demonstrated an 8-fold longer half-life and 16-fold greater exposure than the non-capped variant IM1222, while showing a 300-fold higher dose threshold for cytokine release. This validates the CAPTN-3 masking strategy, which aims to minimize toxicity while maintaining anti-tumor potency.
Key figures
- Clinical timeline
- 2027
- Exposure improvement
- 16-fold
- Clearance improvement
- 14-fold
- Half life improvement
- 8-fold
- Cytokine safety margin
- 300-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.